by GlyTherix | Jul 16, 2020
16th July 2020: Sydney • Project boasts a dream team of world class partners across antibody manufacturing and clinical trials • Grant will support development of national capability in manufacture and distribution of radioimmuno-oncology drugs • GlyTherix’s...
by GlyTherix | May 19, 2020
Tuesday 19th May 2020: Sydney GlyTherix Ltd (GlyTherix) is pleased to report publication of four new peer reviewed papers covering both basic science as well as pre-clinical studies around our proprietary novel target, Glypican-1 and our lead antibody to this target,...
by GlyTherix | Feb 14, 2018
Facebook Twitter Google+ LinkedIn A poster on Glypican-1 as a novel immunotherapeutic target in genitourinary cancers was presented by Dr Douglas Campbell, Minomic’s head of R&D at the 2018 ASCO Genitourinary Cancers Symposium in San Francisco. Preliminary...